



Clinical trial results:

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus

Summary

EudraCT number	2017-001489-53
Trial protocol	ES LT DE BG HU PL PT
Global end of trial date	05 November 2020

Results information

Result version number	v1 (current)
This version publication date	21 May 2021
First version publication date	21 May 2021

Trial information

Trial identification

Sponsor protocol code	CNT01275SLE3001
-----------------------	-----------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03517722
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Janssen Research and Development, LLC
Sponsor organisation address	Welsh & McKean Roads, P.O. Box 776, Spring House, United States, PA 19477
Public contact	Clinical Registry Group, Janssen Research and Development, LLC, ClinicalTrialsEU@its.jnj.com
Scientific contact	Clinical Registry Group, Janssen Research and Development, LLC, ClinicalTrialsEU@its.jnj.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	05 November 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	05 November 2020
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The main objective of this study was to evaluate the efficacy of ustekinumab in subjects with active systemic lupus erythematosus (SLE) who had not adequately responded to one or more standard-of-care treatments.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with good clinical practices and applicable regulatory requirements. The safety assessments included vital signs, general and targeted physical examination, adverse events (AEs)/serious adverse events (SAEs), study agent administration reaction, concomitant medications, laboratory tests including pregnancy testing, chemistry, coagulation, hematology, and urinalysis, and immunogenicity.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 May 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 28
Country: Number of subjects enrolled	Bulgaria: 27
Country: Number of subjects enrolled	Canada: 2
Country: Number of subjects enrolled	China: 8
Country: Number of subjects enrolled	Colombia: 17
Country: Number of subjects enrolled	Germany: 19
Country: Number of subjects enrolled	Hungary: 14
Country: Number of subjects enrolled	Japan: 46
Country: Number of subjects enrolled	Lithuania: 21
Country: Number of subjects enrolled	Poland: 38
Country: Number of subjects enrolled	Portugal: 1
Country: Number of subjects enrolled	Korea, Republic of: 5
Country: Number of subjects enrolled	Russian Federation: 30
Country: Number of subjects enrolled	Serbia: 42
Country: Number of subjects enrolled	Spain: 10
Country: Number of subjects enrolled	South Africa: 12
Country: Number of subjects enrolled	Taiwan: 25

Country: Number of subjects enrolled	Thailand: 12
Country: Number of subjects enrolled	Ukraine: 30
Country: Number of subjects enrolled	United States: 129
Worldwide total number of subjects	516
EEA total number of subjects	130

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	4
Adults (18-64 years)	485
From 65 to 84 years	27
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 1029 subjects were screened, out of which 516 subjects were randomized to the study. Out of 516, 208 subjects were randomized to placebo and 308 subjects were randomized to ustekinumab.

Period 1

Period 1 title	Through Week 52
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo - Ustekinumab

Arm description: -

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Subjects received matching placebo to ustekinumab IV at Week 0, followed by matching placebo to ustekinumab SC at Week 8 and q8w thereafter through Week 48 during double-blind period. Eligible subjects who entered the extension period will cross-over to receive 90 mg ustekinumab SC q8w through Week 160.

Arm title	Ustekinumab
------------------	-------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Ustekinumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Subjects received ustekinumab approximately 6 milligram per kilogram (mg/kg) intravenously (IV) based on body weight-range at Week 0 followed by 90 mg ustekinumab subcutaneously (SC) at Week 8 and every 8 weeks (q8w) thereafter through Week 48 during double-blind period. Eligible subjects who will enter the extension period will continue to receive 90 mg ustekinumab SC q8w through Week 160.

Number of subjects in period 1	Placebo - Ustekinumab	Ustekinumab
Started	208	308
Completed	105	153
Not completed	103	155
Adverse event, serious fatal	1	4
Consent withdrawn by subject	11	11
Adverse event, non-fatal	2	3
Initiated prohibited medication	-	2
Other	4	3
Pregnancy	-	1
Study terminated by sponsor	76	120
Serious Adverse Event, non-fatal	6	8
Lack of efficacy	2	3
Protocol deviation	1	-

Period 2

Period 2 title	After Week 52
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo - Ustekinumab
Arm description: -	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use, Subcutaneous use
Dosage and administration details:	
Subjects received matching placebo to ustekinumab IV at Week 0, followed by matching placebo to ustekinumab SC at Week 8 and q8w thereafter through Week 48 during double-blind period. Eligible subjects who entered the extension period will cross-over to receive 90 mg ustekinumab SC q8w through Week 160.	
Arm title	Ustekinumab
Arm description: -	
Arm type	Experimental

Investigational medicinal product name	Ustekinumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Subjects received ustekinumab approximately 6 milligram per kilogram (mg/kg) intravenously (IV) based on body weight-range at Week 0 followed by 90 mg ustekinumab subcutaneously (SC) at Week 8 and every 8 weeks (q8w) thereafter through Week 48 during double-blind period. Eligible subjects who will enter the extension period will continue to receive 90 mg ustekinumab SC q8w through Week 160.

Number of subjects in period 2^[1]	Placebo - Ustekinumab	Ustekinumab
Started	88	137
Completed	0	0
Not completed	88	137
Consent withdrawn by subject	1	1
Study terminated by sponsor	87	134
Serious Adverse Event, non-fatal	-	1
Lack of efficacy	-	1

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: These are the subjects who entered the extension phase at Week 52.

Baseline characteristics

Reporting groups

Reporting group title	Placebo - Ustekinumab
-----------------------	-----------------------

Reporting group description: -

Reporting group title	Ustekinumab
-----------------------	-------------

Reporting group description: -

Reporting group values	Placebo - Ustekinumab	Ustekinumab	Total
Number of subjects	208	308	516
Title for AgeCategorical Units: subjects			
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	3	1	4
Adults (18-64 years)	191	294	485
From 65 to 84 years	14	13	27
85 years and over	0	0	0
Title for AgeContinuous Units: years			
arithmetic mean	44.5	42.9	
standard deviation	± 12.31	± 11.38	-
Title for Gender Units: subjects			
Female	191	291	482
Male	17	17	34

End points

End points reporting groups

Reporting group title	Placebo - Ustekinumab
Reporting group description: -	
Reporting group title	Ustekinumab
Reporting group description: -	
Reporting group title	Placebo - Ustekinumab
Reporting group description: -	
Reporting group title	Ustekinumab
Reporting group description: -	

Primary: Percentage of Subjects Achieving an Systemic Lupus Erythematosus Responder Index-4 (SRI-4) Composite Response at Week 52

End point title	Percentage of Subjects Achieving an Systemic Lupus Erythematosus Responder Index-4 (SRI-4) Composite Response at Week 52 ^[1]
End point description:	
End point type	Primary
End point timeframe:	
Week 52	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No formal statistical hypothesis testing was planned for this study due to the descriptive nature of this study.

End point values	Placebo - Ustekinumab	Ustekinumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	116	173		
Units: percentage of subjects				
number (not applicable)	65	76		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to Week 182

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.0
--------------------	------

Reporting groups

Reporting group title	Placebo (Prior to entering LTE)
-----------------------	---------------------------------

Reporting group description:

Subjects only received placebo administration through Week 52 double blinded period. Data prior to the first administration of ustekinumab, or through the last follow-up if the subject did not receive any ustekinumab, were included.

Reporting group title	Placebo to Ustekinumab (After entering LTE)
-----------------------	---

Reporting group description:

Subjects only received placebo administration through Week 52 double blinded period, and crossed over to ustekinumab in the extension period. Data from the first administration of ustekinumab through the last follow-up were included.

Reporting group title	Ustekinumab (Through Week 176)
-----------------------	--------------------------------

Reporting group description:

Subjects received ustekinumab administration through Week 52 double blinded period, and continued to receive ustekinumab in the extension period. Data from the first administration of ustekinumab through the last follow-up were included.

Serious adverse events	Placebo (Prior to entering LTE)	Placebo to Ustekinumab (After entering LTE)	Ustekinumab (Through Week 176)
Total subjects affected by serious adverse events			
subjects affected / exposed	28 / 208 (13.46%)	5 / 88 (5.68%)	44 / 307 (14.33%)
number of deaths (all causes)	1	0	5
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acoustic Neuroma			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diffuse Large B-Cell Lymphoma			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric Cancer			

subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aortic Aneurysm			
subjects affected / exposed	0 / 208 (0.00%)	1 / 88 (1.14%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep Vein Thrombosis			
subjects affected / exposed	0 / 208 (0.00%)	1 / 88 (1.14%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemic Shock			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Lupus Vasculitis			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Hyperemesis Gravidarum			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Benign Prostatic Hyperplasia			

subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian Cyst			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute Respiratory Failure			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	2 / 307 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lupus Pleurisy			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural Effusion			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary Hypertension			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory Failure			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			

Fall			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Implantation Complication			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion Related Reaction			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Patella Fracture			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post Procedural Fever			
subjects affected / exposed	0 / 208 (0.00%)	1 / 88 (1.14%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post Procedural Haemorrhage			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic Rupture			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Ulna Fracture			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			

Acute Myocardial Infarction			
subjects affected / exposed	2 / 208 (0.96%)	1 / 88 (1.14%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	0 / 208 (0.00%)	1 / 88 (1.14%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac Failure			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	2 / 307 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pericardial Effusion			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Amnesia			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embololic Stroke			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial Paralysis			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic Stroke			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Neuropsychiatric Lupus			

subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	2 / 307 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	2 / 208 (0.96%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Retinal Detachment			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visual Impairment			
subjects affected / exposed	0 / 208 (0.00%)	1 / 88 (1.14%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal Hernia			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal Pain			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastritis			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis Acute			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small Intestinal Obstruction			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatorenal Syndrome			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Dermal Cyst			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersensitivity Vasculitis			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pemphigoid			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic Epidermal Necrolysis			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Renal and urinary disorders			
Haematuria			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lupus Nephritis			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephritic Syndrome			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	2 / 307 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurogenic Bladder			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal Colic			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Intervertebral Disc Protrusion			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Osteonecrosis			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Systemic Lupus Erythematosus			
subjects affected / exposed	4 / 208 (1.92%)	0 / 88 (0.00%)	2 / 307 (0.65%)
occurrences causally related to treatment / all	0 / 4	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Covid-19			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	4 / 307 (1.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Diverticulitis			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis Staphylococcal			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Gastroenteritis			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	2 / 307 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes Zoster			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected Bite			

subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nosocomial Infection			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	4 / 307 (1.30%)
occurrences causally related to treatment / all	1 / 1	0 / 0	2 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary Tuberculosis			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Infection			
subjects affected / exposed	2 / 208 (0.96%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 2	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral Infection			

subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vulval Cellulitis			
subjects affected / exposed	0 / 208 (0.00%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Electrolyte Imbalance			
subjects affected / exposed	1 / 208 (0.48%)	0 / 88 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo (Prior to entering LTE)	Placebo to Ustekinumab (After entering LTE)	Ustekinumab (Through Week 176)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	60 / 208 (28.85%)	3 / 88 (3.41%)	79 / 307 (25.73%)
Nervous system disorders			
Headache			
subjects affected / exposed	14 / 208 (6.73%)	1 / 88 (1.14%)	19 / 307 (6.19%)
occurrences (all)	15	1	42
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	19 / 208 (9.13%)	2 / 88 (2.27%)	24 / 307 (7.82%)
occurrences (all)	23	2	32
Upper Respiratory Tract Infection			
subjects affected / exposed	17 / 208 (8.17%)	0 / 88 (0.00%)	25 / 307 (8.14%)
occurrences (all)	21	0	31
Urinary Tract Infection			
subjects affected / exposed	20 / 208 (9.62%)	0 / 88 (0.00%)	26 / 307 (8.47%)
occurrences (all)	25	0	34

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Study was early terminated for futility.
--

Notes: